Page 415 - Avian Virology: Current Research and Future Trends

406 | Index
L adaptive immunity and 385, 386, 387
LABEL (Lineage Assignment By Extended Learning) 20 aviadenovirus genome and 297
Laboratory of genetics and physiology 2 (LGP2) 293, 378, 379 CAV and 269, 272
Lactic acid bacteria expression system 223 cell lines derived from 254, 256
LAMP (loop-mediated isothermal amplification) 201, 239, 273, 334 chicken MHC and 385
LANA (latent associated nuclear antigen) 354 diagnosis 357–58
Laniidae 15 fowlpox genome compared to that of 373
Laridae 14 genome manipulation 355–56
Latency associated transcripts (LATs) 320, 352, 353 genome replication 347–54
Latent associated nuclear antigen (LANA) 354 genes associated with DNA replication 349
Leiothrichidae 15 genomic structure 350
Leucocyte receptor complex (LRC) 382 proteins associated with viral DNA replication 349–50
Leucocytes 383 proteins essential for viral DNA replication 348–49
Leukaemia 231, 236, 354, 355 unique regulatory proteins and RNAs 350–54
Leukosis 231. See also Avian leukosis virus (ALV) HVT and 387
Leukosis/sarcoma (L/S) group of diseases 231, 235 ILTV and 319, 325, 327, 332
LGP2 (Laboratory of genetics and physiology 2) 293, 378, 379 infectious agent 345–47
Lineage Assignment By Extended Learning (LABEL) 20 classification 345–46
Live-attenuated vaccines 163, 222, 335–36, 387. See also Vaccines and genome structure and organization 347, 348
vaccination morphogenesis 346–47
Local immunity 125, 159, 331 virion structure 346, 347
Long pentraxin PTX3 378 innate immunity and 377, 379, 380, 382, 383
Loop-mediated isothermal amplification (LAMP) 201, 239, 273, 334 life cycle 356–57
Lories 197 MDV-1 345–48, 350–51, 353, 355, 358, 359
Lorikeets 197 MDV-2 345–48, 353, 358, 359
Low pathogenicity avian influenza (LPAI) 13, 377 MDV-3 345–46, 348, 353
Low pathogenicity avian influenza viruses (LPAIV) 1, 4, 16, 20, 23–25, Meq protein 345, 350–51, 354, 355, 356, 358
379, 382 molecular oncogenesis 354–55
LRC (leucocyte receptor complex) 382 pathogenesis 357
L/S (leukosis/sarcoma) group of diseases 231, 235 vaccines 337, 345, 358–59, 387, 388 (See also under Vaccines and
Lymphocytes 383–84 vaccination)
Lymphoid leukosis 231, 232, 234, 236, 237 as vaccine vector 70, 223, 240, 337, 358–59
Lymphomas 345, 352, 353, 354, 356, 357–58, 373 Marker-rescue method 355
Lymphoproliferative lesions 357 MAS (malabsorption syndrome) 194
Lymphosarcomatosis 231 Mastadenovirus 284–87, 290, 292–98, 303–4
Lysozyme 158, 378 MAVS (mitochondrial antiviral signalling) 12
MAvV (Metaavulavirus) 44–45, 86, 87, 106–10
M MBL (mannose-binding lectin) 378
Macaca fascicularis 106 MCM3 (minichromosome maintenance complex component 3) 259
Macrobrachium nipponense 180 MDA5. See Melanoma differentiation-associated gene 5 (MDA5)
Macrophages 380, 383, 384, 385, 387 MDT (mean death time) 68
Macropinocytosis 56, 214, 286, 383 MDV. See Marek’s disease virus (MDV)
Magellanic penguins 89, 370 Mean death time (MDT) 68
Mahlapitsi virus (MAHLV) 180 Measles virus 61, 122
Main protease (Mpro) 147 Megalaimidae 15
Major histocompatibility complex (MHC) MeHV-1 (Meleagrid herpesvirus 1) 297, 345, 346, 348
adaptive immune response and 384–88 Melanoma differentiation-associated gene 5 (MDA5)
antigen presentation 386–87 adenoviruses and 293
BF-BL region 385, 386 ALV and 237
in chickens (B) 219, 221, 237, 385–88 IBDV and 216–22
class I 260, 380, 382, 384, 385–86, 387, 388 IBV and 152, 158
class II 380, 384, 385, 386, 387, 388 innate host responses and 378, 379
and genetic resistance 377 NDV and 51
IFNγ and 380 Meleagrid herpesvirus 1 (MeHV-1) 297, 345, 346, 348
innate immune response and 388 Meleagris gallopavo 110, 195–96
Rfp-Y region 385 Melopsittacus undulatus 197
Malabsorption syndrome (MAS) 192, 193, 194 MERS-CoV 147
Malassimilation 194 Mesoniviridae 134
Mallard ducks 6–7, 156, 188–89, 196, 197, 199 Metaavulavirus (MAvV) 44–45, 86, 87, 95, 106–10
Mammalian orthoreovirus (MRV) 180, 187, 190 Metaparamyxovirinae 44, 85
MAMPs (microbe associated molecular patterns) 378 Metapneumovirus 119
Mannose-binding lectin (MBL) 378 Metapneumoviruses (MPVs) 119–22. See also Avian metapneumoviruses
Mannose receptors 383 (AMPV); Human metapneumovirus (HMPV)
MAPK (mitogen-activated protein kinase) pathway 12, 13, 153–54, 219, ‘one health’ projects 119, 127
293, 351 type I 120, 123
Marble spleen disease (MSD) 283, 304, 305, 306 type II 120, 123
Marble spleen disease virus (MSDV) 284, 286, 299, 305 MHC. See Major histocompatibility complex (MHC)
Mardivirus 325, 345 MHV (mouse hepatitis virus) 140–41, 144–46, 151, 153, 155, 158
Marek’s disease (MD) 70, 202, 223, 232, 238, 272, 345–46, 353 Microbe-associated molecular patterns (MAMPs) 378
Marek’s disease virus (MDV) 345–64 MicroRNAs (miRNAs) 211, 218–21, 223–24, 292, 320, 329, 352–53
Mimoreovirus 180